Phase III - A Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) in Patients with Severe COVID-19 Pneumonia (COVACTA)

Trial Identifier: NCT04320615

Trial Status: Completed

Actual Enrollment: 450 patients

Study Arms and Intervention

Inclusion Criteria

Exclusion Criteria

Please refer to clinicaltrials.gov for the most current study information including site locations, inclusion, and exclusion criteria.

 

Phase III - A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

Trial Identifier: NCT04409262

Trial Status: Recruiting

Estimated Enrollment: 450 patients

Study Arms and Intervention

Inclusion Criteria

Exclusion Criteria

Please refer to clinicaltrials.gov for the most current study information including site locations, inclusion, and exclusion criteria.

 

Phase III - A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)

Trial Identifier: NCT04372186

Trial Status: Recruiting

Estimated Enrollment: 379 patients

Study Arms and Intervention

Inclusion Criteria

Exclusion Criteria

Please refer to clinicaltrials.gov for the most current study information including site locations, inclusion, and exclusion criteria.

 

Phase II - A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia (MARIPOSA)

Trial Identifier: NCT04363736

Trial Status: Active, not recruiting

Estimated Enrollment: 100 patients

Study Arms and Intervention

Inclusion Criteria

Exclusion Criteria

Please refer to clinicaltrials.gov for the most current study information including site locations, inclusion, and exclusion criteria.